Villa-Zapata Lorenzo, Warholak Terri, Slack Marion, Malone Daniel, Murcko Anita, Runger George, Levengood Michael
Facultad de Farmacia, Universidad de Concepción, Barrio Universitario s/n, Concepción, Chile.
Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, College of Pharmacy, 1295 N. Martin, Tucson, AZ, 85721, USA.
Int Urol Nephrol. 2016 Feb;48(2):249-56. doi: 10.1007/s11255-015-1183-x. Epub 2015 Dec 11.
Predictive models allow clinicians to identify higher- and lower-risk patients and make targeted treatment decisions. Microalbuminuria (MA) is a condition whose presence is understood to be an early marker for cardiovascular disease. The aims of this study were to develop a patient data-driven predictive model and a risk-score assessment to improve the identification of MA.
The 2007-2008 National Health and Nutrition Examination Survey (NHANES) was utilized to create a predictive model. The dataset was split into thirds; one-third was used to develop the model, while the other two-thirds were utilized for internal validation. The 2012-2013 NHANES was used as an external validation database. Multivariate logistic regression was performed to create the model. Performance was evaluated using three criteria: (1) receiver operating characteristic curves; (2) pseudo-R (2) values; and (3) goodness of fit (Hosmer-Lemeshow). The model was then used to develop a risk-score chart.
A model was developed using variables for which there was a significant relationship. Variables included were systolic blood pressure, fasting glucose, C-reactive protein, blood urea nitrogen, and alcohol consumption. The model performed well, and no significant differences were observed when utilized in the validation datasets. A risk score was developed, and the probability of developing MA for each score was calculated.
The predictive model provides new evidence about variables related with MA and may be used by clinicians to identify at-risk patients and to tailor treatment. The risk score developed may allow clinicians to measure a patient's MA risk.
预测模型可帮助临床医生识别高风险和低风险患者,并做出有针对性的治疗决策。微量白蛋白尿(MA)被认为是心血管疾病的早期标志物。本研究的目的是开发一种基于患者数据的预测模型和风险评分评估方法,以改进对MA的识别。
利用2007 - 2008年国家健康与营养检查调查(NHANES)创建预测模型。数据集被分成三部分;三分之一用于开发模型,另外三分之二用于内部验证。2012 - 2013年的NHANES用作外部验证数据库。进行多变量逻辑回归以创建模型。使用三个标准评估模型性能:(1)受试者工作特征曲线;(2)伪R(2)值;(3)拟合优度(Hosmer-Lemeshow)。然后使用该模型绘制风险评分图表。
使用具有显著关系的变量开发了一个模型。纳入的变量包括收缩压、空腹血糖、C反应蛋白、血尿素氮和饮酒情况。该模型表现良好,在验证数据集中使用时未观察到显著差异。制定了风险评分,并计算了每个评分发生MA的概率。
该预测模型提供了与MA相关变量的新证据,临床医生可利用它来识别有风险的患者并制定个性化治疗方案。所开发的风险评分可使临床医生衡量患者患MA 的风险。